Compound News and Research

RSS

University of Sydney researchers identify new type of medication for osteoporosis

University of Sydney researchers have discovered a new and promising treatment for osteoporosis which is easily delivered in water soluble form.

20 Nov 2013

Enhancing the NMDA glutamate receptor causes antidepressant-like effects

Thirteen years ago, an article in this journal first reported that the anesthetic medication, ketamine, showed evidence of producing rapid antidepressant effects in depressed patients who had not responded to prior treatments. Ketamine works by blocking one of the targets for the neurotransmitter glutamate in the brain, the N-methyl-D-aspartate (NMDA) glutamate receptor.

20 Nov 2013

Study finds resveratrol in colored vegetables, fruits may block effects of methamphetamine

Studies have shown that resveratrol, a natural compound found in colored vegetables, fruits and especially grapes, may minimize the impact of Parkinson's disease, stroke and Alzheimer's disease in those who maintain healthy diets or who regularly take resveratrol supplements.

20 Nov 2013

Topokine initiates Phase 2 clinical trial of XAF5 Gel for double chin treatment

Topokine Therapeutics has initiated dosing in a Phase 2, randomized controlled clinical trial of XAF5 Gel for reduction of excess submental fat, commonly known as "double chin." XAF5 Gel is a proprietary skin formulation of a compound already known to reduce fat around the human eye. Study participants are applying XAF5 Gel or placebo once a night to skin under the chin.

20 Nov 2013

Study finds patients treated with varespladib drug more likely to experience cardiovascular events

Patients with acute coronary syndrome who were treated with the experimental drug varespladib were more likely to experience additional cardiovascular events - including sudden death, heart attack and stroke - than those treated with placebo, according to research from the Cleveland Clinic Coordinating Center for Clinical Research (C5Research).

19 Nov 2013

Atopix recruits first patient in OC459 Phase 2 trial for treatment of atopic dermatitis

Atopix Therapeutics Ltd, a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the recruitment of the first patient in a six month Phase 2 clinical trial of its lead compound OC459 in moderate-to-severe atopic dermatitis (eczema).

19 Nov 2013

Study suggests potential new treatment for seizures

A study out today in the journal Nature Medicine suggests a potential new treatment for the seizures that often plague children with genetic metabolic disorders and individuals undergoing liver failure. The discovery hinges on a new understanding of the complex molecular chain reaction that occurs when the brain is exposed to too much ammonia.

17 Nov 2013

Mount Sinai biologist wins NIH Director's New Innovator Awards for High-Risk, High Reward Research

Arvin Dar, PhD, structural and chemical biologist in oncological sciences at the Icahn School of Medicine at Mount Sinai, is one of 41 national recipients of the prestigious National Institutes of Health (NIH) Director's New Innovator Awards for High-Risk, High Reward Research. The award will support Dar's research into Ras-dependent cancers, specifically investigating how to combat mutations in Ras, a protein implicated in at least one of every five cancers.

16 Nov 2013

Study suggests novel approach for treatment of advanced metastatic prostate cancers

New study suggests that selective blockade of CRM1-dependent nuclear export represents a completely novel, tumour metastasis-selective approach for the treatment of advanced metastatic prostate cancers.

16 Nov 2013

Extracts made from herbs may improve learning and memory, study finds

Enhanced extracts made from special antioxidants in spearmint and rosemary improve learning and memory, a study in an animal model at Saint Louis University found.

15 Nov 2013

Research could refine next generation of drugs to help treat dementia

A £1.1 million grant to understand how one of the brain's key neurotransmitters called 'acetylcholine' influences brain activity has been awarded to University of Bristol researchers. The Wellcome Trust award will help scientists understand more precisely how the release of acetylcholine is changing brain cell activity to influence memory and cognition.

15 Nov 2013

New microbicide gel formulation shows promise for safe vaginal and rectal administration to prevent HIV

Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus (HIV).

15 Nov 2013

Small molecule compound shows significant success in controlling polyomaviruses

A team of scientists reports that a small molecule compound showed significant success in controlling the infectivity and spread of three polyomaviruses in human cell cultures. To date there has been no medicine approved to treat such viruses, which prey on transplant recipients, people with HIV, and others whose immune systems have been weakened.

15 Nov 2013

Dermalogix awarded SBIR Phase II grant to develop topical drug candidate for atopic dermatitis

Signum Dermalogix, Inc. announced that the National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the company a Small Business Innovation Research Phase II grant totaling $1.6 million for the development of a topical drug candidate for atopic dermatitis.

15 Nov 2013

Svelte completes enrollment in drug-eluting coronary stent Integrated Delivery System study

Svelte Medical Systems today announced enrollment of the final patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier Technology) clinical study. DIRECT II is a prospective, randomized study comparing the safety and efficacy of the Svelte drug-eluting coronary stent Integrated Delivery System (IDS) to the Medtronic Resolute Integrity drug-eluting stent in 159 patients at 19 investigative sites.

From Medtronic 14 Nov 2013

Novel IRL-1620 compound may be useful in treating Alzheimer's disease

The novel compound IRL-1620 may be useful in treating Alzheimer's disease as it has been shown to prevent cognitive impairment and oxidative stress in animal models. This research is being presented at the 2013 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in San Antonio, Nov. 10-14.

14 Nov 2013

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.

13 Nov 2013

Merck Serono signs co-development and commercialization agreement for BeiGene-290

Merck Serono, the biopharmaceutical division of Merck, today announced that a global licensing, co-development, and commercialization agreement for BeiGene-290 has been signed with BeiGene Co., Ltd., a biotech research and development company in Beijing, China.

13 Nov 2013

Cellectricon introduces Dynaflow Resolve Temperature Control system for ion channel research

Cellectricon, a leading provider of advanced cell-based screening technologies and services, launches the Dynaflow Resolve Temperature Control system at Neuroscience 2013 (San Diego), booth #933.

From Cellectricon 12 Nov 2013

Study provides new evidence underlining the significance of bitter taste perception

It's no coincidence that the expression "to leave a bitter taste in one's mouth" has a double meaning; people often have strong negative reactions to bitter substances, which, though found in healthful foods like vegetables, can also signify toxicity. For this reason, the ability to sense bitterness likely played an important role in human evolution.

12 Nov 2013

Compound News and Research

University of Sydney researchers identify new type of medication for osteoporosis

Enhancing the NMDA glutamate receptor causes antidepressant-like effects

Study finds resveratrol in colored vegetables, fruits may block effects of methamphetamine

Topokine initiates Phase 2 clinical trial of XAF5 Gel for double chin treatment

Study finds patients treated with varespladib drug more likely to experience cardiovascular events

Atopix recruits first patient in OC459 Phase 2 trial for treatment of atopic dermatitis

Study suggests potential new treatment for seizures

Mount Sinai biologist wins NIH Director's New Innovator Awards for High-Risk, High Reward Research

Study suggests novel approach for treatment of advanced metastatic prostate cancers

Extracts made from herbs may improve learning and memory, study finds

Research could refine next generation of drugs to help treat dementia

New microbicide gel formulation shows promise for safe vaginal and rectal administration to prevent HIV

Small molecule compound shows significant success in controlling polyomaviruses

Dermalogix awarded SBIR Phase II grant to develop topical drug candidate for atopic dermatitis

Svelte completes enrollment in drug-eluting coronary stent Integrated Delivery System study

Novel IRL-1620 compound may be useful in treating Alzheimer's disease

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

Merck Serono signs co-development and commercialization agreement for BeiGene-290

Cellectricon introduces Dynaflow Resolve Temperature Control system for ion channel research

Study provides new evidence underlining the significance of bitter taste perception

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News